Eli Lilly & Co. (LLY.US) announced that its weight-loss drug called Zepbound outperformed competitor Novo Nordisk A/S’ Wegovy (NOVOB.DK) in the first head-to-head study of the two drugs.
In the Lilly-sponsored study, people treated with Zepbound lost an average of 20% of their body weight in 72 weeks, while those receiving Wegovy lost 14%. The results confirm earlier studies of both drugs, which indicated a stronger effect of Zepbound. Full results will be published next year, Eli Lilly said. The official study document can be found here.
Immediately following the announcement, Novo Nordisk shares lost 0.7% in value, while Eli Lily shares gained nearly 2% before the session began.
LLY shares gain before the opening of the session on Wall Street. Source: Yahoo Finance
Meanwhile, Novo Nordisk shares are bouncing off the resistance zone set by the 50-day EMA (blue curve) and losing nearly 1.2% today. Source: xStation
The material on this page does not constitute financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other specific needs. All information provided, including opinions, market research, mathematical results and technical analyzes published on the Website or transmitted To you by other means, it is provided for information purposes only and should in no way be construed as an offer or solicitation for a transaction in any financial instrument, nor should the information provided be construed as advice of a legal or financial nature on which any investment decisions you make should be based exclusively To your level of understanding, investment objectives, financial situation, or other specific needs, any decision to act on the information published on the Website or sent to you by other means is entirely at your own risk if you In doubt or unsure about your understanding of a particular product, instrument, service or transaction, you should seek professional or legal advice before trading. Investing in CFDs carries a high level of risk, as they are leveraged products and have small movements Often the market can result in much larger movements in the value of your investment, and this can work against you or in your favor. Please ensure you fully understand the risks involved, taking into account investments objectives and level of experience, before trading and, if necessary, seek independent advice.
